Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective

Author： Nuijten Mark   Andress Dennis L.   Marx Steven E.   Sterz Raimund  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.5, 2009-05, pp. : 1221-1234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low-Dose Alfacalcidol Controls Secondary Hyperparathyroidism in Predialysis Chronic Kidney Disease

By  

Nephron Clin Pract, Vol. 114, Iss. 4, 2010-01 ,pp. : c268-c276

Karger

Access to resources Recommend Favorite

Secondary Hyperparathyroidism Is Associated with Higher Cost of Care among Chronic Kidney Disease Patients with Cardiovascular Comorbidities

By  

Nephron Clin Pract, Vol. 105, Iss. 4, 2007-01 ,pp. : c159-c164

Karger

Access to resources Recommend Favorite

Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

By  

Nephron Clin Pract, Vol. 117, Iss. 2, 2010-08 ,pp. : c151-c159

Karger

Access to resources Recommend Favorite

Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism

By  

THERAPEUTIC APHERESIS AND DIALYSIS, Vol. 19, Iss. 3, 2015-06 ,pp. : 225-234

John Wiley & Sons Inc

Access to resources Recommend Favorite

Calcitriol Regresses Cardiac Hypertrophy and QT Dispersion in Secondary Hyperparathyroidism on Hemodialysis

By  

Nephron Clin Pract, Vol. 102, Iss. 1, 2005-09 ,pp. : c21-c29

Karger

Access to resources Recommend Favorite